Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine

Gadolinium-conjugated star-block copolymer polylysine-modified polyethylenimine as high-performance T 1 MR imaging blood pool contrast agents

Core-shell copolymers have received widespread attention because of their unique properties, such as suitable for surface modification and increasing the functionality. Thus, they have been increasingly used in many fields including biomedical, pharmaceutical, electronics and optics. Here, a new core-shell copolymer system was developed to synthesize potential blood pool contrast agent (CA) for magnetic resonance imaging (MRI). The novel CA with high T ₁ relaxivity was synthesized by conjugating gadolinium (Gd) chelators onto star-block copolymer polyethylenimine-grafted poly(l-lysine) (PEI-PLL) nanoparticles (NPs). The T ₁ relaxivity of PEI-PLL-DTPA-Gd NPs measured on a 7.0 T small animal MRI scanner was 8.289 mM^-1 s^-1, higher than that of T ₁ contrast agents widely used in the clinic, such as Gd-DTPA (also known as Magnevist, r ₁ = 4.273 mM^-1 s^-1). These results show that PEI-PLL-DTPA-Gd exhibits more efficient T ₁ MR contrast enhancement compared to Gd-DTPA. More importantly, the PEI-PLL-DTPA-Gd core-shell NPs exhibited extremely low toxicity when measured against the HepG2 cell line over a similar concentration rang of Magnevist. In in vivo experiments, PEI-PLL-DTPA-Gd not only displayed good T ₁ contrast enhancement for the abdominal aorta, but also showed prolonged blood circulation time compared with Gd-DTPA, which should enable longer acquisition time, for MR and MR angiographic images, with high resolution in clinical practice. PEI-PLL-DTPA-Gd NPs have potential to serve as high T ₁ relaxivity blood pool MRI CA in the clinic.

Enhancing magnetic resonance imaging with contrast agents for ultra-high field strengths

Contrast agents are diagnostic tools that often complement magnetic resonance imaging. At ultra-high field strengths (≥7 T), magnetic resonance imaging is capable of generating desirable high signal-to-noise ratios, but clinically available contrast agents are less effective at ultra-high field strengths relative to lower fields. This gap in effectiveness demands the development of contrast agents for ultra-high field strengths. In this minireview, we summarize contrast agents reported during the last three years that focused on ultra-high field strengths.

Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model

RATIONALE AND OBJECTIVES

To assess the applicability of a novel macromolecular polyethylene glycol (PEG)-core gadolinium contrast agent for monitoring early antiangiogenic effects of bevacizumab using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI).

MATERIALS AND METHODS

Athymic rats (n = 26) implanted with subcutaneous human melanoma xenografts underwent DCE-MRI at 2.0 T using two different macromolecular contrast agents. The PEG core cascade polymer PEG12,000-Gen4-(Gd-DOTA)16, designed for clinical development, was compared to the prototype, animal-only, macromolecular contrast medium (MMCM) albumin-(Gd-DTPA)35. The treatment (n = 13) and control (n = 13) group was imaged at baseline and 24 hours after a single dose of bevacizumab (1 mg) or saline to quantitatively assess the endothelial-surface permeability constant (K(PS), μL⋅min⋅100 cm(3)) and the fractional plasma volume (fPV,%), using a two-compartment kinetic model.

RESULTS

Mean K(PS) values, assessed with PEG12,000-Gen4-(Gd-DOTA)16, declined significantly (P < .05) from 29.5 ± 10 μL⋅min⋅100 cm(3) to 10.4 ± 7.8 μL⋅min⋅100 cm(3) by 24 hours after a single dose of bevacizumab. In parallel, K(PS) values quantified using the prototype MMCM albumin-(Gd-DTPA)35 showed an analogous, significant decline (P < .05) in the therapy group. No significant effects were detected on tumor vascularity or on microcirculatory parameters in the control group between the baseline and the follow-up scan at 24 hours.

CONCLUSION

DCE-MRI enhanced with the novel MMCM PEG12,000-Gen4-(Gd-DOTA)16 was able to monitor the effects of bevacizumab on melanoma xenografts within 24 hours of a single application, validated by the prototype, animal-only albumin-(Gd-DTPA)35. PEG12,000-Gen4-(Gd-DOTA)16 may be a promising candidate for further clinical development as a macromolecular blood pool contrast MRI agent.

The influence of PAMAM-OH dendrimers on the activity of human erythrocytes ATPases

Dendrimers are a relatively new and still not fully examined group of polybranched polymers. In this study polyamidoamine dendrimers with hydroxyl surface groups (PAMAM-OH) of third, fourth and fifth generation (G3, G4 and G5) were examined for their ability to influence the activity of human erythrocyte plasma membrane adenosinetriphosphatases (ATPases). Plasma membrane ATPases are a group of enzymes related, among others, to the maintenance of ionic balance inside the cell. An inhibition of their activity may result in a disturbance of cell functioning. Two of examined dendrimers (G4 and G5) were found to inhibit the activity of Na(+)/K(+) ATPase and Ca(2+) ATPase by 20-30%. The observed effect was diminished when higher concentrations of dendrimers were used. The experiment with the use of pyrene as fluorescent probe sensitive to the changes in microenvironment's polarity revealed that it was an effect of dendrimers' self-aggregation. Additional studies showed that PAMAM-OH dendrimers were able to decrease the fluidity of human erythrocytes plasma membrane. Obtained results suggest that change in plasma membrane fluidity was not caused by the dendrimer-lipid interaction, but dendrimer-protein interaction. Different pattern of influence of dendrimers on ATPases activity and erythrocyte membrane fluidity suggests that observed change in ATPases activity is not a result of dendrimer-lipid interaction, but may be related to direct interaction between dendrimers and ATPases.

Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans

PURPOSE

To evaluate very small superparamagnetic iron oxide particles (VSOP-C184) as blood-pool contrast agent for coronary MR angiography (CMRA) in humans.

MATERIALS AND METHODS

Six healthy volunteers and 14 patients with suspected coronary artery disease underwent CMRA after administration of VSOP-C184 at the following doses: 20 μmol Fe/kg (4 patients), 40 μmol Fe/kg (5 patients), 45 μmol Fe/kg (6 healthy volunteers), and 60 μmol Fe/kg (5 patients). In healthy volunteers, contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), and vessel edge definition (VED) of contrast-enhanced CMRA were compared with non-contrast-enhanced CMRA. In patients, a per-segment intention-to-diagnose evaluation of contrast-enhanced CMRA for detection of significant coronary stenosis (≥50%) was performed.

RESULTS

Three healthy volunteers (45 μmol Fe/kg VSOP-C184) and two patients (60 μmol Fe/kg VSOP-C184) had adverse events of mild or moderate intensity. VSOP-C184 significantly increased CNR (15.1 ± 4.6 versus 6.9 ± 1.9; P = 0.010), SNR (21.7 ± 5.3 versus 15.4 ± 1.6; P = 0.048), and VED (2.3 ± 0.6 versus 1.2 ± 0.2; P < 0.001) compared with non-contrast-enhanced CMRA. In patients, contrast-enhanced CMRA yielded sensitivity, specificity, and diagnostic accuracy for detection of significant coronary stenosis of 86.7%, 71.0%, 73.1%, respectively.

CONCLUSION

CMRA using VSOP-C184 was feasible and yielded moderate diagnostic accuracy for detection of significant coronary stenosis within this proof-of-concept setting.

MR angiography of collateral arteries in a hind limb ischemia model: comparison between blood pool agent Gadomer and small contrast agent Gd-DTPA

The objective of this study was to compare the blood pool agent Gadomer with a small contrast agent for the visualization of ultra-small, collateral arteries (diameter<1 mm) with high resolution steady-state MR angiography (SS-MRA) in a rabbit hind limb ischemia model. Ten rabbits underwent unilateral femoral artery ligation. On days 14 and 21, high resolution SS-MRA (voxel size 0.49×0.49×0.50 mm³) was performed on a 3 Tesla clinical system after administration of either Gadomer (dose: 0.10 mmol/kg) or a small contrast agent (gadopentetate dimeglumine (Gd-DTPA), dose: 0.20 mmol/kg). All animals received both contrast agents on separate days. Selective intra-arterial x-ray angiograms (XRAs) were obtained in the ligated limb as a reference. The number of collaterals was counted by two independent observers. Image quality was evaluated with the contrast-to-noise ratio (CNR) in the femoral artery and collateral arteries. CNR for Gadomer was higher in both the femoral artery (Gadomer: 73±5 (mean ± SE); Gd-DTPA: 40±3; p<0.01) and collateral arteries (Gadomer: 18±4; Gd-DTPA: 9±1; p = 0.04). Neither day of acquisition nor contrast agent used influenced the number of identified collateral arteries (p = 0.30 and p = 0.14, respectively). An average of 4.5±1.0 (day 14, mean ± SD) and 5.3±1.2 (day 21) collaterals was found, which was comparable to XRA (5.6±1.7, averaged over days 14 and 21; p>0.10). Inter-observer variation was 24% and 18% for Gadomer and Gd-DTPA, respectively. In conclusion, blood pool agent Gadomer improved vessel conspicuity compared to Gd-DTPA. Steady-state MRA can be considered as an excellent non-invasive alternative to intra-arterial XRA for the visualization of ultra-small collateral arteries.

Contrast agents used in cardiovascular magnetic resonance imaging: current issues and future directions

Cardiovascular MRI is being increasingly used in the evaluation of ischemic heart disease, cardiac masses, complex congenital heart disease, and morphologic evaluation of the vascular anatomy throughout the body. Many and varied contrast media may be used to increase the sensitivity and specificity of detecting and evaluating various pathologies, and a knowledge of the different mechanisms of action, distributions and safety profiles of these agents is required for safe and effective imaging. This article reviews the currently available magnetic resonance (MR) contrast media, discusses the risks and benefits, and gives illustrated examples of current clinical applications in cardiovascular disease. A literature search covered the period 1990 to the present with the use of multiple databases including MEDLINE, PUBMED, SciSearch and Google Medical. All identified studies containing information relevant to the topic of cardiovascular MRI and cardiovascular MR contrast agents and their uses and properties were evaluated. Evaluation was limited to studies in English. The conclusions were that the use of contrast agents vastly increases the diagnostic yield, sensitivity and specificity of cardiovascular MRI in the non-invasive diagnosis of the full breadth of cardiovascular pathology. The use of contrast MRI for investigating ischemic heart disease, cardiac masses, and congenital heart disease and in angiography is now well established, and the referring physician, cardiologist, or radiologist requires an in-depth knowledge of the safety profiles and correct dosing of commonly prescribed contrast agents. As the number of MR contrast agents on the market continues to increase, knowledge of the basic mechanism of action is vital for keeping abreast of how new and emerging agents will affect clinical practice in the future.

Contrast-enhanced whole-heart coronary MRA using Gadofosveset 3.0 T versus 1.5 T

RATIONALE AND OBJECTIVES

To compare contrast-enhanced coronary magnetic resonance angiography (MRA) at 3.0 T with the same technique performed at 1.5 T using the contrast agent gadofosveset.

MATERIALS AND METHODS

In this prospective randomized study, 19 healthy male volunteers (mean age 28 years, mean weight 79.8 kg), after signing informed consents, underwent contrast-enhanced inversion recovery three-dimensional fast low angle shot (FLASH) MRA at 1.5 and at 3.0 T. Prospective electrocardiogram-triggering was combined with adaptive respiratory gating. For contrast-enhanced images, the intravascular contrast agent gadofosveset was used. Acquisition time, signal-to-noise ratio (SNR) of coronary blood, contrast-to-noise ratio (CNR) between coronaries and adjacent myocardium or epicardial fat and image quality were analyzed for statistical differences by using a two-tailed paired-sample t-test. The ratio calculations were based on measurements performed on the raw data and the image quality was blinded and independently evaluated by two experienced radiologists using a five-point scale.

RESULTS

The mean values for the acquisition time were 14.58 +/- 0.1 minutes at 1.5 T and 16.40 +/- 0.2 minutes at 3.0 T. Overall SNR of all evaluated coronary segments proved higher at 3.0 T compared to 1.5 T (74.0 +/- 42.1 at 3.0 T vs. 50.2 +/- 20.2 at 1.5 T, P = .04). Overall CNR between coronaries and myocardium was significantly increased at 3.0 T in comparison to 1.5 T (40.1 +/- 21.9 at 3.0 T vs. 24.4 +/- 17.2 at 1.5 T, P = .01). Between the two methods, no significant difference in overall CNR between coronaries and epicardial fat was observed (P = .08, NS). The 3.0 T MRA demonstrated superior overall image quality with respect to 1.5 T (2.28 +/- 0.71 at 3.0 T vs. 1.92 +/- 0.38 at 1.5T, P = .004).

CONCLUSION

The use of higher field strength, 3.0 T instead of 1.5 T, resulted in similar CNR between coronaries and epicardial fat, higher SNR values and CNR between blood and myocardium, as well as an improved overall image quality, when gadofosveset in combination with electrocardiogram and respiratory triggering for coronary MRA was used.

Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography

BACKGROUND

A comprehensive evaluation of myocardial ischemia requires measures of both oxygen supply and demand. Positron emission tomography (PET) is currently the gold standard for such evaluations, but its use is limited because of its ionizing radiation, limited availability, and high cost. A cardiac MRI method was developed for assessing myocardial oxygenation. The purpose of this study was to evaluate and validate this technique compared with PET during pharmacological stress in a canine model of coronary artery stenosis.

METHODS AND RESULTS

Twenty-one beagles and small mongrel dogs without coronary artery stenosis (controls) or with moderate to severe acute coronary artery stenosis underwent MRI and PET imaging at rest and during dipyridamole vasodilation or dobutamine stress to induce a wide range of changes in cardiac perfusion and oxygenation. MRI first-pass perfusion imaging was performed to quantify myocardial blood flow and volume. The MRI blood oxygen level-dependent technique was used to determine the myocardial oxygen extraction fraction during pharmacological hyperemia. Myocardial oxygen consumption was determined by the Fick law. In the same dogs, (15)O-water and (11)C-acetate were used to measure myocardial blood flow and myocardial oxygen consumption, respectively, by PET. Regional assessments were performed for both MR and PET. MRI data correlated nicely with PET values for myocardial blood flow (R(2)=0.79, P<0.001), myocardial oxygen consumption (R(2)=0.74, P<0.001), and oxygen extraction fraction (R(2)=0.66, P<0.01).

CONCLUSIONS

Cardiac MRI methods may provide an alternative to radionuclide imaging in settings of myocardial ischemia. Our newly developed quantitative MRI oxygenation imaging technique may be a valuable noninvasive tool to directly evaluate myocardial energetics and efficiency.

Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy

Dendrimers are characterized by a combination of high end-group functionality and a compact, precisely defined molecular structure. These characteristics can be used in biomedical applications, for example, for the amplification or multiplication of effects on a molecular level, or to create extremely high local concentrations of drugs, molecular labels, or probe moieties. A brief summary of the current state of the art in the field is given, and focuses on the application of dendrimers both in diagnostics as well as in therapy. In diagnostics, dendrimers that bear GdIII complexes are used as contrast agents in magnetic resonance imaging. DNA dendrimers have potential for routine use in high-throughput functional genomic analysis, as well as for DNA biosensors. Dendrimers are also being investigated for therapeutics, for example, as carriers for controlled drug delivery, in gene transfection, as well as in boron neutron-capture therapy. Furthermore, the antimicrobial activity of dendrimers has been studied.

Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset

OBJECTIVES

The purpose of this study was to compare contrast-enhanced (CE) whole-heart coronary magnetic resonance angiography (MRA) at 3.0 T using gadofosveset to noncontrast-enhanced steady-state free precession (SSFP) coronary MRA at 1.5 T.

MATERIALS AND METHODS

A prospective randomized study was conducted among 20 healthy male volunteers. The same group of subjects underwent CE whole heart MRA at 3.0 T employing a 3D FLASH sequence with IR prepulse after gadofosveset injection as well as noncontrast-enhanced coronary MRA at 1.5 T using a 3D SSFP sequence with T2-preparation. Both techniques were performed using prospective ECG-triggering and adaptive respiratory gating. Acquisition time, signal-to-noise ratio of coronary blood, contrast-to-noise ratio (CNR) between coronaries and adjacent myocardium or epicardial fat, and image quality were evaluated in each case.

RESULTS

A significant increase of the overall CNR between coronary blood and adjacent myocardium was measured on images acquired at 3 T in comparison to 1.5 T. The mean values were 38.9 +/- 19.6 and 26.3 +/- 15.4, respectively (P[r] < 0.005). There was no significant difference in CNR between coronary blood and epicardial fat. The mean image quality for the proximal and mid coronary segments was not statistically different between 1.5 T and 3.0 T (P > 0.05), however, the distal coronary segments were rated significantly higher for the CE MRA at 3.0 T (P = 0.02). The average acquisition time (15.29 +/- 5.73 minutes at 1.5 T vs. 17.29 +/- 5.18 minutes at 3 T) and overall image quality (2.15 +/- 0.49 at 1.5 T vs. 2.35 +/- 0.39 at 3 T) were similar for both methods.

CONCLUSIONS

CE whole-heart coronary MRA at 3.0 T demonstrated higher overall CNR between coronary blood and myocardium and an improved image quality of the distal coronary segments compared with noncontrast-enhanced SSFP coronary MRA at 1.5 T.

Gadofosveset-enhanced magnetic resonance angiography

Gadofosveset (Vasovist^®, Bayer Schering Pharma AG, Berlin/Germany) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to albumin providing extended intravascular enhancement compared wth existing extracellular magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

Three-dimensional breathhold magnetization-prepared TrueFISP: a pilot study for magnetic resonance imaging of the coronary artery disease

PURPOSE

X-ray angiography is currently the standard test for the assessment of coronary artery disease. A substantial minority of patients referred for coronary angiography have no significant coronary artery disease. The purpose of this work was the evaluation of the accuracy of a three-dimensional (3D) breathhold coronary magnetic resonance angiography (MRA) technique in detecting hemodynamically significant coronary artery stenoses in a patient population with x-ray angiographic correlation.

MATERIALS AND METHODS

Sequential subjects (n = 33, M/F = 22/11, average age = 57) who were referred for conventional coronary angiography were enrolled in the study. The study protocol was approved by our institutional review board. Each subject gave written informed consent. Volume-targeted 3D breathhold coronary artery scans with ECG-triggered, segmented True Fast Imaging with Steady-state Precession (TrueFISP) were acquired for the left main (LM), left anterior descending (LAD), and right coronary arteries (RCAs). Coronary MRA was evaluated with conventional angiography as the gold standard.

RESULTS

The overall sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for diagnosing any hemodynamically significant coronary artery disease (> or =50% diameter reduction) with coronary MRA was 87%, 57%, 72%, 68%, and 80%, respectively. The sensitivity of the technique in the LM, LAD, and RCA was 100%, 83%, and 100%, respectively. The NPV of the technique in the LM, LAD, and RCA was 100%, 82%, and 100%, respectively.

CONCLUSIONS

Three-dimensional breathhold True Fast Imaging with Steady-state Precession is a promising technique for coronary artery imaging. It has a relatively high sensitivity and NPV. Results of this study warrant further technical improvements and clinical evaluation of the technique.

Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents

Macromolecular gadolinium (Gd)(III) complexes have a prolonged blood circulation time and can preferentially accumulate in solid tumors, depending on the tumor blood vessel hyperpermeability, resulting in superior contrast enhancement in magnetic resonance (MR) cardiovascular imaging and cancer imaging as shown in animal models. Unfortunately, safety concerns related to these agents’ slow elimination from the body impede their clinical development. Polydisulfide Gd(III) complexes have been designed and developed as biodegradable macromolecular magnetic resonance imaging (MRI) contrast agents to facilitate the clearance of Gd(III) complexes from the body after MRI examinations. These novel agents can act as macromolecular contrast agents for in vivo imaging and excrete rapidly as low-molecular-weight agents. The rationale and recent development of the novel biodegradable contrast agents are reviewed here. Polydisulfide Gd(III) complexes have relatively long blood circulation time and gradually degrade into small Gd(III) complexes, which are rapidly excreted via renal filtration. These agents result in effective and prolonged in vivo contrast enhancement in the blood pool and tumor tissue in animal models, yet demonstrate minimal Gd(III) tissue retention as the clinically used low-molecular-weight agents. Structural modification of the agents can readily alter the contrast-enhancement kinetics. Polydisulfide Gd(III) complexes are promising for further clinical development as safe, effective, biodegradable macromolecular MRI contrast agents for cardiovascular and cancer imaging, and for evaluation of therapeutic response.

Magnetic resonance coronary angiography with Vasovist: in-vivo T1 estimation to improve image quality of navigator and breath-hold techniques

The purpose of the study was to estimate T1 values of blood and myocardium after a single injection of Vasovist and to assess Vasovist for magnetic resonance coronary angiography (MRCA). For all exams 0.05 mmol/kg of Vasovist was injected. T1 values of blood and myocardium were estimated over 30 min after injection. Twelve volunteers were examined on a 1.5-T Siemens system using a SSFP sequence with incrementally increasing inversion times for T1-estimation and a breath-hold 3D IR-FLASH sequence for MRCA. Eleven examinations were performed on 1.5-T Philips system using the Look-Locker approach for T1 estimation and a whole-heart inversion-prepared, 3D SSFP sequence for MRCA. SNR, CNR and image quality were assessed. T1 values of blood (5 min: 230 ms vs. 30 min: 275 ms) and myocardium (5 min: 99 ms vs. 30 min: 130 ms) increased over time. Whereas the blood SNR (1 min: 23.6 vs. 30 min: 21.2) showed no significant differences, the blood-to-myocardium CNR (1 min: 18.1 vs. 30 min: 13.8) and the image quality (1 min: 2.9 vs. 30 min: 3.8) degraded over time. Due to long plasma half-time the T1-shortening effect of Vasovist remains effective over 30 min, which allows for multiple breath-hold or high-resolution MRCA.

Improvement of quantification of myocardial first-pass perfusion mapping: a temporal and spatial wavelet denoising method

Mapping of myocardial blood flow (MBF) with first-pass perfusion imaging is becoming an important tool in the study of coronary artery disease. In this study a wavelet-based denoising method was developed to improve the accuracy of pixel-by-pixel MBF maps. We performed an in vivo study in five stenotic dogs with 70% stenosis in the left coronary arteries. First-pass perfusion imaging sessions were performed by administering the intravascular contrast agent Gadomer at rest and during dipyridamole-induced vasodilation. Color microspheres (MS) were injected into the dogs to measure MBF at the same time. After denoising was performed, the signal-to-noise ratio (SNR) of the first-pass perfusion image improved by approximately 180%, whereas spatial variation of MBF maps decreased 38%. It was also found that the correlation of MBFs measured by MRI with the MS method indicates a significant improvement with the denoising method (R2 increased from 0.24 to 0.78, P < .001). This suggests that the wavelet denoising method may be an effective way to increase the accuracy of pixel-by-pixel MBF quantification and reduce spatial variation, and may be applicable to other forms of noise-sensitive image analysis.

Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging

Poly(L-glutamic acid) (PGA)-cystamine-[gadolinium (Gd)-DO3A] was prepared in high yield with a high Gd-DO3A conjugation efficiency. Approximately 55% of the carboxylic groups in PGA were loaded with Gd-DO3A via cystamine as the spacer. Cystamine can be readily cleaved by endogenous thiols to release the Gd(III) chelates from the conjugate facilitating Gd(III) excretion after the magnetic resonance imaging (MRI). The contrast-enhanced MRI with PGA-cystamine-(Gd-DO3A) was investigated in mice bearing MDA-MB-231 breast carcinoma xenografts. PGA-1,6-hexanediamine-(Gd-DO3A), a paramagnetic polymer conjugate of a nondegradable spacer, was used as a control. Both conjugates resulted in similar contrast enhancement in the heart, vasculature, liver and kidneys in the first hour post injection. More substantial signal intensity reduction was observed for PGA-cystamine-(Gd-DO3A) in these organs than PGA-1,6-hexanediamine-(Gd-DO3A) due to release of the Gd chelates from PGA-cystamine-(Gd-DO3A) after the cleavage of the disulfide spacer by the endogenous thiols. Both conjugates resulted in similar tumor enhancement with approximately 70% increased signal intensity in the tumor periphery and 10-40% increased signal intensity in tumor interstitium. No cross-reaction was observed between PGA-cystamine-(Gd-DO3A) and human serum albumin, a plasma protein containing a cysteine residue. PGA-cystamine-(Gd-DO3A) resulted in significantly lower Gd(III) tissue retention than PGA-1,6-hexanediamine-(Gd-DO3A) 10 days after the injection in the mice (P<.05). The conjugation of Gd(III) chelates to biomedical copolymers via the degradable disulfide spacer resulted in significant contrast enhancement in the blood pool and tumor tissue but minimal long-term Gd(III) tissue retention.

Comparison of Gradient-Echo and Steady-State Free Precession for Coronary Artery Magnetic Resonance Angiography Using a Gadolinium-Based Intravascular Contrast Agent

OBJECTIVES

Intravascular contrast agents may offer longer imaging times and better vessel visualization over conventional extravascular agents for magnetic resonance coronary angiography. The purpose of this study was to evaluate the effect of intravascular contrast (B-22956/1) on coronary visualization. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were compared in inversion-recovery (IR)-prepared FLASH (fast low-angle shot) and IR-trueFISP (true fast imaging with steady-state precession) sequences before and after contrast.

MATERIALS AND METHODS

Numeric simulations were performed to compare blood signals in IR-trueFISP and IR-FLASH sequences. Coronary imaging was performed in 15 swine.

RESULTS

Postcontrast CNR was improved 23% with breathhold IR-FLASH and 55% with breathhold IR-trueFISP as compared with precontrast trueFISP. With free-breathing, long TR IR-FLASH provided 131% and 55.8% higher SNR and 132% and 58.7% increased CNR compared with IR-FLASH with shorter TR and IR-trueFISP, respectively.

CONCLUSION

Intravascular contrast agents improve CNR and vessel visualization in coronary magnetic resonance angiography with IR-FLASH and IR-trueFISP.

Single-session magnetic resonance coronary angiography and myocardial perfusion imaging using the new blood pool compound B-22956 (gadocoletic acid): initial experience in a porcine model of coronary artery disease

OBJECTIVE

The objective of this study was to evaluate a new blood pool contrast agent, B-22956, for detecting myocardial perfusion abnormality and coronary artery stenosis by magnetic resonance imaging (MRI) in 1 setting.

MATERIALS AND METHODS

Coronary artery atherosclerotic stenoses were created in 6 miniswine. Myocardial first-pass perfusion imaging was performed with a bolus injection of 0.015 mmol/kg B-22956 during pharmacologic stress followed by postcontrast coronary artery imaging after another injection of B-22956/1. The total doses for the 6 pigs were 0.1 mmol/kg (n=3) and 0.15 mmol/kg (n=3). Perfusion upslope maps were analyzed and MR coronary artery images were reviewed by 2 readers.

RESULTS

For all 6 pigs, the normalized upslopes of the perfusion curves were 0.83+/-0.12, 0.74+/-0.15, and 0.52+/-0.05 (P<0.01 vs. normal) with normal or mild (<50% area stenosis), moderate (<50% and <75%), and severe stenosis (>75%), respectively. Mean signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in right coronary artery images improved 90% and 200%, respectively, with a total dose of 0.1 mmol/kg of B-22956. Excellent agreements (kappa=0.82) were achieved for evaluating the grade of stenosis between MR postcontrast coronary artery images and histopathology by 2 reviewers.

CONCLUSION

The MR blood pool contrast agent B-22956 demonstrated the ability for detecting myocardial perfusion abnormalities and coronary artery stenosis in 1 setting.

Gadomer-enhanced MR Imaging in the Detection of Microvascular Obstruction: Alleviation with Nicorandil Therapy

PURPOSE

To evaluate Gadomer-enhanced magnetic resonance (MR) imaging in the quantification of small microvascular obstruction regions and determine if nicroandil alleviates the formation of microvascular obstruction.

MATERIALS AND METHODS

Approval of the institutional committee on animal research was obtained, and this study complied with guidelines for care and use of animals. Rats underwent coronary artery occlusion and reperfusion. After 24 hours, Gadomer-enhanced T1-weighted spin-echo MR imaging was used to define microvascular obstruction in animals in control and nicorandil groups. Sequential MR images obtained at two midventricular levels were acquired to measure microvascular obstruction and ischemically injured regions and monitor diffusive and/or convective transport of Gadomer in microvascular obstruction regions. Two investigators working in consensus and using threshold signal intensity measured differentially enhanced regions. Left-ventricular (LV) end-systolic and end-diastolic MR images obtained at the same two midventricular levels were used to measure regional wall thickening and systolic reduction in LV relative volumes. Agreement and correlation between MR imaging and postmortem data were determined with Bland-Altman and linear regression analyses. Animals were sacrificed 3 minutes after intravenous injection of blue dye.

RESULTS

On Gadomer-enhanced MR images, two differentially enhanced regions were observed in ischemically injured myocardium, namely, the hypoenhanced region and the surrounding hyperenhanced region. Hypoenhanced regions at MR imaging and unstained regions at blue dye administration were identical 3 minutes after administration (17% +/- 1 and 17% +/- 2; P = .6; r = 0.98). In the control group, Gadomer provided a prolonged imaging window (eg, 6 minutes) for accurately quantifying small microvascular obstruction regions. Microvascular obstruction was observed in all animals in the control group and 27% of animals in the nicorandil group. Microvascular obstruction regions were smaller in the nicorandil group (eg, 3% +/- 1) than in the control group (eg, 17% +/- 2) (P < .001). Hyper- and hypoenhanced regions were also smaller (eg, 20% +/- 2) in rats in the nicorandil group than in those in the control group (37% +/- 4, P < .001). Improvement in LV function in the nicorandil group is likely related to alleviation and reduction in infarct size.

CONCLUSION

Gadomer-enhanced MR imaging can be used to quantify small microvascular obstruction regions 24 hours after reperfusion. Intravenous therapy with nicorandil reduces formation of microvascular obstruction regions.

Coronary arteries at 3.0 T: Contrast-enhanced magnetization-prepared three-dimensional breathhold MR angiography

PURPOSE

To evaluate the efficacy of contrast-enhanced coronary magnetic resonance angiography (MRA) at 3.0 T.

MATERIALS AND METHODS

Nine healthy human volunteers were studied on a 3.0-T whole-body MR system. A three-dimensional, breathhold, magnetization-prepared, segmented, gradient-echo sequence was used, with injection of 20 mL gadopentetate dimeglumine for each three-dimensional slab. Imaging parameters were optimized based on computer simulations. Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), depicted coronary artery length, lumen diameter, and imaging sharpness with contrast agent were evaluated. SNR and CNR were compared to the results from a previous 1.5-T study.

RESULTS

A 53% increment in SNR and a 305% enhancement in CNR were measured with contrast. Vessel length and sharpness depicted were higher and the lumen diameter was lower (all P values < 0.05) in postcontrast images. Compared to previous results from 1.5-T, the SNR, CNR, and vessel sharpness were enhanced at 3.0 T with higher spatial resolution.

CONCLUSION

Contrast-enhanced, three-dimensional, coronary MRA at 3.0 T is a promising technique for diagnosing coronary artery diseases. Patient studies are necessary to evaluate its clinical utility.

VX2 Carcinoma in Rabbits after Radiofrequency Ablation: Comparison of MR Contrast Agents for Help in Differentiating Benign Periablational Enhancement from Residual Tumor

PURPOSE

To prospectively compare the accuracy of a blood pool agent, SH L 643A, with that of gadopentetate dimeglumine in differentiating benign periablational enhancement from residual tumor in VX2 carcinomas in rabbits after radiofrequency (RF) ablation.

MATERIALS AND METHODS

Experiment was approved by the animal care committee. Sequential MR images were obtained before and with SH L 643A (17 000 Da, 0.05 mmol/kg) and, after a 24-hour interval, gadopentetate dimeglumine (546 Da, 0.1 mmol/kg) in 12 rabbits with VX2 carcinoma in the back muscle prior to (n = 12) and early (n = 12), 1 week (n = 8), and 4 weeks (n = 4) after RF ablation. RF ablation was performed with output of 90 W but at less than 300 seconds to ensure incomplete tumor ablation. The pathologic specimens were sectioned in the same plane as MR imaging, and the enhancement ratios (ie, the ratios of postcontrast to precontrast signal intensity) and the microvessel densities of residual tumor and benign periablational enhancement were assessed.

RESULTS

With SH L 643A, the peak enhancement ratios of residual tumor (1.64 +/- 0.31 [standard deviation]) were significantly higher than those of benign periablational enhancement (0.97 +/- 0.16) (P < .001). With gadopentetate dimeglumine, the peak enhancement ratios of residual tumor (1.82 +/- 0.33) were not different from those of benign periablational enhancement (1.71 +/- 0.36). In benign periablational enhancement, enhancement ratios with injection of SH L 643A were lower than those with injection of gadopentetate dimeglumine for all time points up to 30 minutes (P < .05). The microvessel density was 25.72 +/- 5.43 vessels per field of view for residual tumor and 10.37 +/- 2.88 vessels per field of view for benign periablational enhancement (P < .001).

CONCLUSION

Blood pool contrast agent SH L 643A permits more accurate differentiation of benign periablational enhancement from residual tumor compared with the extracellular agent gadopentetate dimeglumine.

Free-breathing, three-dimensional coronary artery magnetic resonance angiography: comparison of sequences

PURPOSE

To compare six free-breathing, three-dimensional, magnetization-prepared coronary magnetic resonance angiography (MRA) sequences.

MATERIALS AND METHODS

Six bright-blood sequences were evaluated: Cartesian segmented gradient echo (C-SGE), radial SGE (R-SGE), spiral SGE (S-SGE), spiral gradient echo (S-GE), Cartesian steady-state free precession (C-SSFP), and radial SSFP (R-SSFP). The right coronary artery (RCA) was imaged in 10 healthy volunteers using all six sequences in randomized order. Images were evaluated by two observers with respect to signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), visible vessel length, vessel edge sharpness, and vessel diameter.

RESULTS

C-SSFP depicted RCA over the longest distance with high vessel sharpness, good SNR, and excellent background suppression. S-GE provided best SNR and CNR in proximal segments, but more vessel blurring and poorer background suppression, resulting in poor visualization of distal segments. R-SSFP images showed good background suppression and best vessel sharpness, but only moderate SNR. C-SGE provided good SNR and reasonable CNR, but lowest vessel sharpness. S-SGE and R-SGE visualized the RCA over the smallest distance, mostly due to vessel blurring and low SNR, respectively.

CONCLUSION

Overall, Cartesian SSFP provided the best image quality with excellent vessel sharpness, visualization of long vessel segments, and good SNR and CNR.

MR Coronary Angiography with SH L 643 A: Initial Experience in Patients with Coronary Artery Disease

PURPOSE

To prospectively assess the accuracy of breath-hold three-dimensional magnetic resonance (MR) coronary angiography with the gadolinium-based intravascular contrast agent SH L 643 A in patients with coronary artery disease.

MATERIALS AND METHODS

Twelve patients (seven men, five women; age range, 46-78 years; mean age, 61.3 years) with angiographically proved coronary artery disease (luminal narrowing >50%) underwent breath-hold three-dimensional MR coronary angiography before and after injection of SH L 643 A (0.1 mmol gadolinium per kilogram body weight). For all MR examinations, signal-to-noise ratio and contrast-to-noise ratio were measured. Image quality was assessed with a four-point scale. Conventional angiograms and MR angiograms were evaluated for depiction of the left main, proximal and middle left anterior descending, proximal left circumflex, and proximal and middle right coronary artery segments in a blinded fashion by two experienced readers in consensus. Results of this evaluation were compared by using a paired Student t test. P < .05 was considered to indicate a statistically significant difference.

RESULTS

For the 72 coronary artery segments, the contrast-to-noise ratio significantly improved after administration of SH L 643 A, compared with the prior ratio (9.8 +/- 5.1 [standard deviation] vs 23.0 +/- 8.7; P < .01), whereas the difference in signal-to-noise ratio did not reach statistical significance (25.2 +/- 11.4 vs 29.5 +/- 9.8; P > .3). Image quality significantly improved from a mean of 2.0 +/- 0.9 for nonenhanced images to 2.9 +/- 0.9 (P < .03) for contrast material-enhanced images. The proportion of segments for which images were nondiagnostic decreased from 38% to 10% with application of SH L 643 A. Overall sensitivity and specificity of contrast-enhanced MR coronary angiography for detection of coronary artery disease were 80% and 93%, respectively, and accuracy was 87%.

CONCLUSION

Use of SH L 643 A improves detection of coronary artery disease at three-dimensional MR coronary angiography.

PEG-g-poly(GdDTPA-co-l-cystine): A Biodegradable Macromolecular Blood Pool Contrast Agent for MR Imaging

Biodegradable PEGylated Gd-DTPA l-cystine copolymers, PEG-g-poly(GdDTPA-co-l-cystine), were prepared and tested as a blood pool contrast agent in mice. The biodegradable macromolecular agent was designed to be broken down into smaller Gd complexes by endogenous thiols via the disulfide-thiol exchange reaction to facilitate the clearance of Gd complexes after the contrast-enhanced MRI examination. Gd-DTPA l-cystine copolymers were synthesized by condensation polymerization of l-cystine and DTPA-dianhydride in water followed by chelating with Gd(OAc)(3). MPEG-NH(2) (MW = 2000) was then conjugated to the polymeric backbone in different ratios. The macromolecular contrast agent was readily degraded with the incubation of l-cysteine. It also demonstrated superior contrast enhancement in the heart and blood vessels as compared to a low molecular weight control agent, Gd-(DTPA-BMA). At 1 h postcontrast, the PEGylated macromolecular agent still showed prominent enhancement, while little contrast enhancement was detectable in the blood pool by the control agent. PEG-g-poly(GdDTPA-co-l-cystine) shows promise as an MR blood pool imaging agent.

Contrast-enhanced MR imaging of the heart: overview of the literature

The use of magnetic resonance (MR) imaging for cardiac diagnosis is expanding, aided by the administration of paramagnetic contrast agents for a growing number of clinical applications. This overview of the literature considers the principles and applications of cardiac MR imaging with an emphasis on the use of contrast media. Clinical applications of contrast material-enhanced MR imaging include the detection and characterization of intracardiac masses, thrombi, myocarditis, and sarcoidosis. Suspected myocardial ischemia and infarction, respectively, are diagnosed by using dynamic first-pass and delayed contrast enhancement. Promising new developments include blood pool contrast media, labeling of myocardial precursor cells, and contrast-enhanced imaging at very high fields.

Assessment of myocardial infarction in pigs using a rapid clearance blood pool contrast medium

Delayed enhancement MRI using extracellular contrast media allows reliable detection of myocardial infarction. If blood pool contrast media like P792 (Vistarem, Guerbet, France), in addition to improving coronary MR angiography, can be shown to also produce delayed enhancement in myocardial infarction they could improve the prerequisites for a comprehensive cardiac MR examination. In this study reperfused myocardial infarction in five minipigs was imaged with an inversion-recovery fast low-angle shot sequence using P792 (0.013 mmol Gd/kg) and the extracellular contrast medium Gd-DOTA (Dotarem, 0.1 mmol Gd/kg, Guerbet). The infarction size determined on MRI using P792 (7.55 +/- 2.31 cm(2)) highly correlated both with histomorphometry (7.81 +/- 2.18 cm(2), r = 0.991, P < 0.002) and with MRI using Gd-DOTA (7.85 +/- 2.35 cm(2), r = 0.978, P < 0.005). Bland-Altman analysis showed that the limit of agreement of MRI using P792 compared to histomorphometry was 3.3 +/- 7.6% of the infarction size. The contrast-to-noise ratio between infarcted and remote myocardium was not significantly different between Gd-DOTA (5.9 +/- 2.4) and P792 (4.4 +/- 1.1, P = 0.5). The blood pool contrast medium P792 allows reliable assessment of viability with good contrast and accuracy.

Contrast-enhanced MR imaging of postoperative scars and VX2 carcinoma in rabbits: comparison of macromolecular contrast agent and gadopentetate dimeglumine

PURPOSE

To compare the magnetic resonance (MR) imaging enhancement patterns of a blood pool contrast agent, SH L 643A, with those of gadopentetate dimeglumine in postoperative scars and VX2 carcinomas in rabbits and to compare these enhancement patterns with microvessel density in pathologic specimens.

MATERIALS AND METHODS

Eighteen rabbits with experimentally induced postoperative scars (n = 12) or VX2 carcinoma (n = 6) in the thighs underwent sequential MR imaging first with gadopentetate dimeglumine and then, 24 hours later, with SH L 643A. The enhancement ratios (ie, the ratios of postcontrast to precontrast signal intensity) and the microvessel densities of postoperative scars and VX2 carcinomas were assessed. Differences were tested for by using the Mann-Whitney U and Wilcoxon signed rank tests.

RESULTS

In postoperative scars, enhancement ratios were consistently lower with injection of SH L 643A than with injection of gadopentetate dimeglumine for up to 30 minutes (P <.05). In postoperative scars, mean peak enhancement ratios were 1.29 +/- 0.15 (SD) with injection of SH L 643A and 1.61 +/- 0.31 with injection of gadopentetate dimeglumine (P <.01). In VX2 carcinomas, the enhancement ratios were not significantly different with injection of SH L 643A than with injection of gadopentetate dimeglumine at all time points. The mean difference between the enhancement ratios of the VX2 carcinomas and postoperative scars was 0.64 +/- 0.10 (range, 0.50-0.77) with SH L 643A and 0.36 +/- 0.16 (range, 0.17-0.66) with gadopentetate dimeglumine (P <.01). The mean microvessel density (in terms of vessels per field of view) was 10.7 +/- 5.5 for postoperative scars and 30.0 +/- 7.7 for VX2 carcinoma (P <.001).

CONCLUSION

The difference between the enhancement ratios of postoperative scars and VX2 carcinomas with SH L 643A was greater than that with gadopentetate dimeglumine. Enhancement ratios at SH L 643A-enhanced MR imaging corresponded well with microvessel density in postoperative scars and VX2 carcinomas.

Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers

PURPOSE

To assess SH L 643A for three-dimensional breath-hold and respiratory-gated magnetic resonance (MR) imaging in the depiction of coronary arteries.

MATERIALS AND METHODS

Twelve healthy male volunteers underwent either three-dimensional breath-hold (n = 6) or respiratory-gated (n = 6) coronary MR angiography before and after intravenous injection of 0.1 mmol SH L 643A per kilogram of body weight. For nonenhanced and contrast material-enhanced examinations, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) measurements were obtained. Image quality was assessed in consensus with a five-point scale. Statistical analysis of nonenhanced and contrast-enhanced images was based on a two-tailed paired Student t test. A P value at the.05 significance level was used.

RESULTS

Overall statistically significant improvement in CNR was observed after administration of SH L 643A compared with that on nonenhanced images (8.7 +/- 5.3 [SD] vs 23.6 +/- 7.2, P <.01). While SNR of contrast-enhanced images showed improvement over that of nonenhanced images, the difference was not statistically significant (25.4 +/- 0.8 vs 30.2 +/- 16.8, P >.2). Image quality improved from a mean of 3.1 +/- 0.8 for nonenhanced images to 4.0 +/- 0.8 (P <.01) for contrast-enhanced images.

CONCLUSION

SH L 643A causes significant improvement of the blood-myocardium contrast enhancement at coronary MR angiography compared with that with nonenhanced sequences.

Three-dimensional navigator coronary MRA with the aid of a blood pool agent in pigs: Improved image quality with inclusion of the contrast agent first-pass

PURPOSE

To evaluate the effect of including the first-pass of a blood pool agent (BPA) on the image quality of three-dimensional navigator coronary MRA.

MATERIALS AND METHODS

A pig model was used to perform: 1) T1 simulation of the BPA, based on actual blood samples, and 2) BPA-enhanced three-dimensional navigator coronary MRA, with or without inclusion of the first-pass of the BPA. The acquisitions with inclusion of the first-pass were timed with the use of a test bolus. The acquisitions without first-pass were started one minute after bolus injection (steady-state). A gradient echo acquisition technique with centric k-space sampling was applied. Comparison of both acquisitions was based on determination of contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), and vessel length.

RESULTS

T1 simulation shows a distinct T1 reduction during first-pass (to a level below 50 msec), increasing to 190 msec during steady-state. Images obtained with first-pass inclusion showed improved CNR (8.6 +/- 1.7 vs. 4.5 +/- 1.8), SNR (11.9 +/- 1.6 vs. 7.4 +/- 2.0), and vessel length (99.2 +/- 10.9 mm vs. 60.5 +/- 21.8 mm) as compared to the acquisitions during steady-state only (all: P< 0.05).

CONCLUSION

The image quality of three-dimensional navigator coronary MRA combined with a gadolinium BPA in pigs is improved when starting the image acquisition during first-pass of the bolus.

High-resolution three-dimensional MR angiography of rodent tumors: morphologic characterization of intratumoral vasculature

PURPOSE

To evaluate high-resolution three-dimensional MR angiography (MRA) for the visualization and morphologic characterization of intratumoral vasculature.

MATERIALS AND METHODS

Two subcutaneous rodent tumor models (human skin carcinoma HaCaT-ras-A-5RT3 grown in nude mice and rat prostate carcinoma R3327-AT1 grown in Copenhagen rats) were examined with a clinical 1.5 T MR-system. For MRA a dedicated high-resolution three-dimensional gradient echo pulse sequence with a voxel size of 166 x 206 x 320 microm(3) was performed after injection of Gadomer-17. The image analysis included a correlation of intratumoral vessels with histology. Signal intensity measurements were performed in the vena cava, the tumor underlying muscle, and in various regions of the tumor. Signal-to-noise-ratios (SNR) and contrast-to-noise-ratios (CNR) were calculated from this measurement.

RESULTS

High-resolution MRA allowed a clear distinction of intratumoral blood vessels. The mouse tumor model tended to be strongly vascularized with several intratumoral blood vessels clearly displayed by MRA. When correlated with histology, these intratumoral blood vessels had a size in the range of 300 to 400 microm. In contrast, rat tumors had only sparse capillary intratumoral blood vessels that could only be demonstrated by histology. In both tumor models, dilated blood vessels were observed in the subcutaneous tissue near the tumor. In general, areas with a strong contrast enhancement correlated with viable, well vascularized tumor regions, whereas non-enhancing tumor areas correlated with tumor necrosis or hypoxic areas.

CONCLUSION

High-resolution three-dimensional MRA allows the visualization of intratumoral vasculature in rodent models. With minimal hardware and software modifications, high-resolution MRA could be performed on a clinical 1.5 T MRI scanner. Morphologic characterization of intratumoral blood vessels could add important insights into the process of tumor angiogenesis.

Improved MR coronary angiography with use of a new rapid clearance blood pool contrast agent in pigs

PURPOSE

To evaluate in an animal model the potential for clinical use of a new rapid clearance blood pool contrast agent to improve free-breathing and breath-hold magnetic resonance (MR) coronary angiography.

MATERIALS AND METHODS

Free-breathing and breath-hold MR coronary angiography were performed in a pig model (n = 9) (a) without use of a contrast agent; (b) with P792 (Guerbet Research, Aulnay Sous Bois, France), a monodisperse monogadolinated macromolecular compound that acts as a blood pool contrast agent with rapid clearance properties; and (c) with an extravascular gadolinium-based contrast agent. This resulted in six imaging options, which were compared in terms of contrast-to-noise ratio (CNR), signal-to-noise ratio, and vessel length measurements by using the Student t test.

RESULTS

Use of P792 improved CNR and visible vessel length significantly with both MR respiratory motion correction approaches, as compared with nonenhanced MR imaging (P <.05). CNR was improved by 76% (from 5.0 to 8.6) with the free-breathing approach and by 34% (from 6.2 to 8.2) with the breath-hold approach. Visible vessel length was increased by 27% (from 79.7 to 99.2 mm) with the free-breathing approach and by 90% (from 48.2 to 86.5 mm) with the breath-hold approach. The P792-enhanced free-breathing approach allowed more distal visualization of the coronary arteries than did the P792-enhanced breath-hold approach (P <.05). Use of the extravascular contrast agent did not improve image quality significantly when compared with that of nonenhanced MR images.

CONCLUSION

Use of P792 improves coronary artery MR imaging in conjunction with free-breathing and breath-hold approaches.

Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease

PURPOSE

To assess the feasibility of Clariscan, an intravascular contrast agent, for free breathing, navigator assisted, high resolution, three-dimensional-magnetic resonance coronary angiography (MRCA) in patients, as extracellular contrast agents are unfavorable for the improvement of image quality.

MATERIALS AND METHODS

MRCA was performed in 10 patients with known coronary artery disease (CAD) with (1-5 mg Fe/kg body weight) and without contrast agent.

RESULTS

Compared to unenhanced images, Clariscan did not improve signal-to-noise (SNR) or contrast-to-noise ratios (CNR) compared to fat or myocardium in the proximal parts of the coronary arteries. However, when analyzing the peripheral parts (>4 cm from origin), CNR(fat) and CNR(myo) improved up to a factor of 1.81 and 5.85, respectively, at a dose of 3 mg Fe/kg body weight, while SNR did not reach statistical significance. The visible length of the coronary arteries was improved from 49 +/- 18 mm to 73 +/- 33 mm. The proximal diameter was reduced from 3.6 +/- 0.8mm to 3.2 +/- 0.8 mm, representing more closely the diameter of 3.1 +/- 0.7 mm measured by quantitative coronary angiography. Of 11 significant stenoses (>50%), eight were identified in the enhanced compared to six in the unenhanced images.

CONCLUSION

The use of Clariscan at a dose of 2-3 mg Fe/kg body weight improves image quality of three-dimensional-MRCA, especially in the peripheral segments, and, thus, the diagnostic accuracy for the detection of CAD.

MR imaging of reperfused myocardial infarction: comparison of necrosis-specific and intravascular contrast agents in a cat model

PURPOSE

To compare T2-weighted and Gadomer-17- and bis-gadolinium mesoporphyrins-enhanced magnetic resonance (MR) images for distinguishing reversibly from irreversibly damaged myocardium in a cat model of reperfused myocardial infarction.

MATERIALS AND METHODS

Twelve cats underwent 90 minutes of occlusion and 90 minutes of reperfusion of the left anterior descending coronary artery. After baseline T1- and T2-weighted MR images were obtained, Gadomer-17-enhanced and bis-gadolinium mesoporphyrins-enhanced T1-weighted images were sequentially obtained for 6 hours and 2 hours, respectively. After MR imaging, all cats were sacrificed for 2,3,5-triphenyltetrazolium chloride (TTC) histochemical tissue staining. Areas of abnormal signal intensity on T2-weighted and Gadomer-17-enhanced and bis-gadolinium mesoporphyrins-enhanced T1-weighted MR images were compared with the areas of infarction seen at TTC histochemical staining by using repeated-measures two-way analysis of variance, linear regression analysis, and Bland-Altman analysis.

RESULTS

Mean areas of abnormally high signal intensity on T2-weighted and Gadomer-17-enhanced T1-weighted MR images (43.9% of the left ventricular surface area +/- 11.9 [SD] and 37.7% +/- 10.1, respectively) were significantly larger than the mean area of myocardial infarction at TTC staining (25.7% +/- 12.5) (P <.001). However, there was excellent correlation between the size of an enhancing area on bis-gadolinium mesoporphyrins-enhanced T1-weighted MR images and that of myocardial infarction at TTC staining (r = 0.916, P <.001).

CONCLUSION

bis-Gadolinium mesoporphyrins-enhanced T1-weighted MR images accurately reflect the area of infarction, whereas the size of infarction is overestimated on T2-weighted and Gadomer-17-enhanced T1-weighted MR images, which seem to depict the periinfarct area as well as the infarct area.

Coronary artery imaging with real-time navigator three-dimensional turbo-field-echo MR coronary angiography: initial experience

PURPOSE

To examine the value of a commercially available three-dimensional (3D) real-time navigator magnetic resonance (MR) coronary angiographic examination for detection of significant coronary artery stenoses, with conventional coronary angiography as the standard of reference.

MATERIALS AND METHODS

Twenty-one patients underwent 3D navigator MR coronary angiography immediately before catheterization. Two observers independently graded image quality on a scale from 1 (unreadable) to 5 (excellent), quantified coronary artery visualization, and evaluated the presence of significant (ie, >50% narrowing) stenoses. kappa statistics were used to assess interobserver agreement, and receiver operating characteristic (ROC) analysis was used to assess stenosis detection.

RESULTS

For two of 21 patients, MR coronary angiogram quality was insufficient for analysis (mean score < 2). For the remaining 19 patients, the mean image quality scores assigned by observers 1 and 2 were 3.3 +/- 1.0 (SD) and 3.2 +/- 0.9, respectively. A mean of 71% of all coronary artery segments were visible at MR coronary angiography, and there was 91% agreement between the observers (kappa = 0.78). Observers 1 and 2 detected significant stenoses (n = 29) at MR coronary angiography with sensitivities of 44.4% and 55.5%, respectively; specificities of 95.1% and 83.7%, respectively; and 80% agreement (kappa = 0.35). Areas under the ROC curve were 0.817 and 0.795 for observers 1 and 2, respectively.

CONCLUSION

Large portions of the coronary arteries can be visualized with MR coronary angiography. Imaging results are not consistently reliable, however. The examination is premature for routine clinical assessment of significant coronary artery stenosis owing to low sensitivity and large observer variability.

Two- and three-dimensional MR coronary angiography with intraarterial injections of contrast agent in dogs: a feasibility study

Magnetic resonance (MR) images of coronary arteries were acquired with an inversion recovery-prepared technique after intraarterial injection of contrast material in five dogs. Real-time two-dimensional projection images were obtained with a temporal resolution of 3 frames per second. Three-dimensional electrocardiographically triggered high-spatial-resolution images were obtained with a fraction of the contrast agent required for intravenous injections. Background tissues were adequately suppressed in all images. On the basis of this experimental data, the optimal contrast agent concentration for two-dimensional real-time projection imaging was 6%. This preliminary work shows that contrast material-enhanced MR angiography with intraarterial injections is feasible with the proposed techniques.

Comparison of contrast-enhanced breath-hold and free-breathing respiratory-gated imaging in three-dimensional magnetic resonance coronary angiography

Suppression of respiratory motion is one of the major challenges of magnetic resonance (MR) coronary angiography. Two approaches to compensate for respiratory motion have often been proposed: breath-hold (BH) and free-breathing respiratory-gated (FBRG) imaging. So far, however, these approaches have never been directly compared. MR coronary angiography was performed in 32 patients with suspected coronary artery disease. MR data were acquired using contrast-enhanced BH and FBRG 3-dimensional MR coronary angiographic techniques. MR images were compared with regard to image quality using quantitative parameters and with regard to accuracy for stenosis detection in the proximal and mid-coronary segments in comparison to x-ray angiography. With regard to image quality, BH was superior to FBRG. Signal-to-noise ratio was 29.1 +/- 10.7 for BH versus 18.8 +/- 9.7 for FBRG (p <0.05) and contrast-to-noise was 18.0 +/- 7.4 for BH versus 11.3 +/- 7.9 for FBRG (p </=0.05). One hundered seventy-one of 224 coronary artery segments (76%) were evaluable in BH compared with 155 of 224 in FBRG (69%). In the evaluable segments, BH demonstrated a sensitivity of 87% (26 of 30 stenoses detected) and specificity of 92% (129 of 141 nonstenotic segments correctly identified), whereas FBRG showed a sensitivity of 60% (15 of 25) and specificity of 89% (115 of 130). Overall accuracy was 91% (155 of 171) for BH and 84% (130 of 155) for FBRG. Sensitivity was significantly higher for BH (p = 0.0320), whereas specificity and overall accuracy were not significantly different. Thus, contrast-enhanced BH MR coronary angiography compares favorably to FBRG imaging with regard to image quality and detection of coronary stenoses.

Initial experience with the intravascular contrast agent NC100150-injection (Clariscan) for breath-hold and navigator-gated magnetic resonance coronary artery imaging

PURPOSE

To examine magnetic resonance coronary artery imaging after NC100150-Injection.

MATERIALS AND METHODS

Breath-hold and navigator-gated images were acquired in five patients.

RESULTS

Breath-hold image quality, coronary artery-fat SDNR, and coronary artery SNR improved. Respiratory artifacts due to reduced liver signal intensity degraded navigator-gated image quality.

CONCLUSION

NC100150-Injection improves breath-hold coronary artery imaging. Navigator-gated acquisitions should use techniques that are insensitive to T2* effects.

Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization

RATIONALE AND OBJECTIVES

Preclinical in-vivo characterization of a newly developed MR contrast medium consisting of very small superparamagnetic iron oxide particles (VSOP) coated with citrate (VSOP-C184).

METHODS

VSOP-C184 (core diameter: 4 nm; total diameter: 8.6 nm; relaxivities in water at 0.94 T (T1) 20.1 and (T2) 37.1 l/[mmol*sec]) was investigated to determine its pharmacokinetics, efficacy, acute single dose toxicity, repeated dose toxicity, and genotoxicity.

RESULTS

The plasma elimination half-life at 0.045 mmol Fe/kg was 21.3 +/- 5.5 minutes in rats and 36.1 +/- 4.2 minutes in pigs, resulting in a T1-relaxation time of plasma of < 100 milliseconds for 30 minutes in pigs. The particles are mainly cleared via the phagocytosing system of the liver. MR angiography at a dose of 0.045 mmol Fe/kg shows an excellent depiction of the thoracic and abdominal vasculature in rats and of the coronary arteries in pigs. The LD50 in mice is > 17.9 mmol Fe/kg. A good tolerance and safety profile was found.

CONCLUSIONS

The experiments indicate, that VSOP-C184 may be a well tolerated and safe contrast medium for MR imaging that can be effectively used for MR angiography including visualization of the coronary arteries.

Single breath-hold multi-slab and cine cardiac-synchronized gadolinium-enhanced three-dimensional angiography

The rest period of the coronary arteries has been shown to be on the order of 120-160 msec. Restriction of the acquisition window in breath-hold cardiac-synchronized gadolinium-enhanced imaging to this duration limits the amount of sampled k-space data and hence the information when compared with conventional gadolinium-enhanced imaging. Two techniques for gadolinium-enhanced cardiac-synchronized angiography were implemented that acquire additional data during the unused portions of the cardiac cycle. Data acquisition is synchronized with the heart cycle and is restricted to a short period of each heart cycle. In a single breath-hold, a multi-slab acquisition (n = 5) allowed ECG-synchronized imaging of the entire heart or a CINE acquisition (n = 5) provided multiple stacks of images at different phases in the cardiac cycle over a smaller area. Preliminary results acquired in healthy volunteers and patients with aortic disease indicate that additional information can be acquired without an increase in breath-hold duration or a reduction in image quality.

Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1

Initial evaluation of a new blood pool agent, B-22956/1, for pulmonary imaging was performed in five domestic pigs with artificial embolism. Pre-embolism 3D pulmonary perfusion images were first acquired by injecting an extravascular agent, gadoteridol. The pulmonary arteries of the pigs were then occluded by the artificial emboli. Post-embolism perfusion scans were subsequently performed by injecting B-22956/1. Additional post-embolism high-spatial-resolution angiograms were also acquired. Parenchyma perfusion deficits were well depicted in the post-embolism perfusion maps. The post-embolism angiography clearly revealed the location and extent of the filling defects in the pulmonary vessels. Signal intensities of perfusion maps on the normal parenchyma were significantly improved (30%) by using B-22956/1, in comparison with perfusion images using gadoteridol (P < 0.01). Many pulmonary angiograms with approximately equal contrast could be obtained even at 22 minutes after the injection of B-22956/1. Our initial results indicate that blood pool agent B-22956/1 may provide opportunities for whole-lung-coverage perfusion mapping and additional high-resolution target angiograms after a single injection.

Contrast-enhanced coronary MR angiography: relationship between coronary artery delineation and blood T1

Contrast-enhanced coronary angiography has become an important technique for magnetic resonance (MR) coronary artery imaging. However, the relationship between the quality of the coronary artery images and blood T1 has not yet been fully explored. In this paper, we assessed this relationship in an animal model by using a prototypical blood pool agent. With accumulated injections of this agent, the blood T1 would be maintained at different levels. The measured blood T1 values in vivo were 147 +/- 3, 82 +/- 6, 48 +/- 4, 40 +/- 3, and 30 +/- 8 msec (N = 7). Fixed and variable flip angle schemes were used in coronary artery imaging. The signal to noise ratios (SNR) of coronary arteries were measured and the image quality was assessed. It was found that blood T1 less than 80 msec might be desired. No statistically significant difference was observed between two flip angle schemes. There was better vessel definition using variable flip angle at blood T1 lower than 50 msec. Understanding this relationship may be beneficial to optimizing image protocol and/or design of blood pool contrast agents for contrast-enhanced coronary angiography.

Magnetic resonance imaging of coronary arteries

Conventional x-ray angiography is presently the gold standard for detecting coronary artery disease. This is a highly invasive procedure with a risk of developing potentially serious complications in addition to its drawback of exposure to ionizing radiation. Magnetic resonance imaging (MRI), a noninvasive method with no known adverse effects, offers exciting possibilities with its ability to acquire true three-dimensional (3D) volume information, image double oblique tomographic planes in the body, and generate excellent soft tissue contrast. These advantages have led to the emergence of MRI as one of the important tools for cardiac imaging. There have been significant improvements in MR systems in recent years that allow for higher gradient subsystems and higher slew rates. This has enabled the realization of magnetic resonance (MR) angiography, which now is consistently used for imaging the head, neck, and body vasculature. Despite all these advances, coronary MR angiography remains a challenge due to the small size of the coronary vessels, their tortuous nature, and the sensitivity of MRI to motion. Different methods, such as electrocardiographic gating and breath-holding or free-breathing approaches using navigators, have been investigated to overcome the cardiac and respiratory motion in coronary MR angiography, respectively. Various pulse sequences have been used in conjunction with these strategies. Injection of extravascular contrast agents led to the improvement of angiographic techniques in terms of higher signal-to-noise and contrast-to-noise ratios. The advent of intravascular agents may improve further the quality and reliability of coronary MR angiography. Recently, true fast imaging with steady-state precession (FISP), an imaging technique with an inherently high imaging efficiency, has emerged as a new angiographic technique. Although coronary MR angiography is still not proven clinically, it is a promising modality for detecting coronary artery disease.

Coronary arteries: magnetization-prepared contrast-enhanced three-dimensional volume-targeted breath-hold MR angiography

A volume-targeted contrast agent-enhanced breath-hold coronary magnetic resonance angiographic technique was optimized and evaluated in 16 volunteers. Substantial increases in coronary signal-to-noise ratio, contrast-to-noise ratio, lengths of depiction, and vessel sharpness were observed on enhanced images. The imaging approach with two 20-mL injections of contrast agent covers the left and right coronary arteries in two breath holds and is a promising method for coronary imaging.